en · de · es
analytical-notes.peptides5388.com › News › Background And Pharmacological Mechanism — Background and Details

Background And Pharmacological Mechanism — Background and Details

By Editorial Desk · published 2026-01-16 · last reviewed 2026-02-15 · News

The short version of analytical standard fits in a sentence. The long version — which is the one that helps — is below.

Reviewed 2026-02-15. Anything still debated is marked as such rather than presented as settled.

Background and Pharmacological Mechanism

Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.

SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.

Background and Mechanism

Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.

SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.

Sr9009 at a glance

PropertyValueNotes
Molecular formulaC20H24ClN3O4SReported for the free base
Molecular weight437.9 g/molCalculated from the formula
Primary targetREV-ERBα and REV-ERBβNuclear receptors involved in circadian regulation
SolubilitySoluble in DMSO and ethanolPoorly soluble in water
Typical storage-20 °C, desiccatedProtect from light and moisture

Identity, Handling, and Regulation

Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.

In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.

Related pages on this site

Analytical Detection and Storage

Quality control for research materials includes identity confirmation by nuclear magnetic resonance and purity assessment by high-performance liquid chromatography. Mass spectrometry provides molecular weight confirmation and can detect related impurities. Purchasers should request a certificate of analysis that lists lot-specific data. Online products advertised for human use often lack such documentation. Distinguishing legitimate research material from mislabeled or contaminated samples is a recurring challenge in independent testing, and independent laboratories may use orthogonal methods to verify identity.

Detection of SR9009 in biological samples usually relies on liquid chromatography coupled to tandem mass spectrometry. This approach separates the compound from matrix components and identifies it by mass transitions. Because SR9009 can undergo metabolism, laboratories often look for both parent drug and specific metabolites. Sample preparation may involve protein precipitation or solid-phase extraction. Method validation examines sensitivity, carryover, and interference from related substances, and reference standards are required for accurate calibration.

Storage recommendations for SR9009 reference material typically specify a freezer at -20 °C or lower, with protection from moisture and light. Repeated freeze-thaw cycles can degrade small molecules and introduce variability. Stock solutions in dimethyl sulfoxide are often aliquoted to avoid repeated handling. Stability studies may examine degradation under heat, humidity, and light exposure. The compound's thiophene and nitro groups can participate in reactions that alter analytical signals over time, so such changes affect quantitative results.

Mechanism and Preclinical Findings

Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.

The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.

SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.

Background from the literature

On 24 June 2013, while the Essendon Football Club was being investigated by the Australian Sports Anti-Doping Authority (ASADA) over the legality of its supplements program during the 2012 AFL season, Watson admitted on the Fox Footy program On the Couch that he believed he was given the substance AOD-9604 during the 2012 season with the assistance of the club. The World Anti-Doping Agency (WADA) released a statement clarifying that AOD-9604 fell into the "S0. Non-Approved Substances" category in their List of Prohibited Substances and Methods. ASADA also stated that the use of AOD-9604 is prohibited for use by athletes in any circumstances. During the investigation, Watson was among the thirty-four present and former Essendon players issued show cause notices by ASADA and infraction notices by the AFL, alleging the use of the banned peptide Thymosin beta-4 during the 2012 season. On 31 March 2015, the AFL Anti-Doping Tribunal found all thirty-four players not guilty of all charges. In January 2016, following an appeal by WADA against the AFL Tribunal's not-guilty finding, Watson, along with the other thirty-three players, had their not-guilty verdict overturned. All thirty-four players were suspended for two years, backdated to November 2016, causing him to miss the entire 2016 AFL season. As Watson had won the 2012 Brownlow Medal, during the season that the supplements program took place, the AFL Commission reviewed the award.

I argue that science is beginning to catch up with Jung who was a pioneer whose insights contribute a great deal to our emerging understanding of human consciousness." In this analysis, Jung's paintings of his visions in The Red Book were compared to the paintings of Ayahuasca visions by the Peruvian shaman Pablo Amaringo. Commenting on research that was being undertaken during the 1950s, Jung wrote the following in a letter to Betty Eisner, a psychologist who was involved in LSD research at the University of California: "Experiments along the line of mescaline and related drugs are certainly most interesting since such drugs lay bare a level of the unconscious that is otherwise accessible only under peculiar psychic conditions. It is a fact that you get certain perceptions and experiences of things appearing either in mystical states or in the analysis of unconscious phenomena." An account of Jung and psychedelics, as well as the importance of Jungian psychology to psychedelic-assisted therapies, is outlined in Scott Hill's 2013 book Confrontation with the Unconscious: Jungian Depth Psychology and Psychedelic Experience. A 2021 article discusses Jung's attitude towards psychedelics, as well as the applicability of his ideas to current research. As the author writes, Jung's "...legitimate reservations about the clinical use of psychedelics are no longer relevant as the field has progressed significantly, devising robust clinical and experimental protocols for psychedelic-assisted therapies.

This enzyme, from peppermint converts (+)-pulegone to a mixture of (–)-menthone and (+)-isomenthone using nicotinamide adenine dinucleotide phosphate (NADPH) as its cofactor. It does not act in the opposite direction

AgNCO + [NH4]Cl → CO(NH2)2 + AgCl This was one of the first artificial syntheses of biological compounds from inorganic starting materials, without the involvement of living organisms. The results of this experiment implicitly discredited vitalism, the theory that the chemicals of living organisms are fundamentally different from those of inanimate matter. This insight was important for the development of organic chemistry. His discovery prompted Wöhler to write triumphantly to Jöns Jakob Berzelius:

Another perspective hypothesis suggests that electromagnetic fields increase in adenosine receptors release, which facilitates neuronal communication. Because A(2A) adenosine receptors control the release of other neurotransmitters (e.g., glutamate and dopamine), this contributes to adjusting neuronal functions. According to the natural neurostimulation hypothesis, energy stimuli induce mitochondrial stress and microvascular vasodilation. These promote increasing Adenosine triphosphate (ATP) protein and oxygenation, inducing synaptic strength. This position explains neuromodulation from different scale levels: from interpersonal dynamics to nonlocal neuronal coupling. According to natural neurostimulation, the innate natural mechanism of physical interactions between the mother and embryo ensures the balanced development of the embryonic nervous system. The drivers of these interactions, the electromagnetic properties of the mother's heart, enable brain waves to interact between the mother's and fetal nervous systems. The electromagnetic and acoustic oscillations of the mother's heart converge the neuronal activity of both nervous systems in an ensemble, shaping harmony from a cacophony of separate oscillations. These interactions synchronize brain oscillations, influencing neuroplasticity in the fetus. During the mother's intentional actions with her environment, these interchanges provide hints to the fetus's nervous system, binding synaptic activity with relevant stimuli.

Sources: en.wikipedia.org

Reference notes

=== EC 1.3.5 With a quinone or related compound as acceptor === EC 1.3.5.1: succinate dehydrogenase (quinone) EC 1.3.5.2: dihydroorotate dehydrogenase (quinone) EC 1.3.5.3: protoporphyrinogen IX dehydrogenase (menaquinone) EC 1.3.5.4: fumarate reductase (quinol) EC 1.3.5.5: 15-cis-phytoene desaturase EC 1.3.5.6: 9,9'-dicis-zeta-carotene desaturase

Anxiety disorders Bobble-head doll syndrome – a sensation that the skull may fall off the cervical spine Clumsiness and motor delay Cognitive and memory decline Double or blurred vision Dysphagia – a sensation of choking Dyspnea Fatigue Lhermitte's sign Migraine Nausea Neck, shoulder, and jaw pain Occipital headaches Orthostatic intolerance Photophobia Syncope Tenderness at base of skull Tinnitus Tremors Palpitations Vertigo or dizziness Weakness of limbs Symptoms are frequently worsened by a Valsalva maneuver or by being upright for long periods of time. Being upright is problematic because gravity allows increased interaction between the brain stem and the top of the spinal column, increasing symptoms. Lying in the supine position can bring short-term relief. Lying supine eliminates the downward gravitational pull, reducing symptoms to some degree. Lying with the feet somewhat higher and head lower can be helpful in symptom reduction.

The general strategy adopted by most present-day competitive bodybuilders is to make muscle gains for most of the year (known as the "off-season") and, approximately 12–14 weeks from competition, lose a maximum of body fat (referred to as "cutting") while preserving as much muscular mass as possible. The bulking phase entails remaining in a net positive energy balance (calorie surplus). The amount of a surplus in which a person remains is based on the person's goals, as a bigger surplus and longer bulking phase will create more fat tissue. The surplus of calories relative to one's energy balance will ensure that muscles remain in a state of anabolism. The cutting phase entails remaining in a net negative energy balance (calorie deficit). The main goal of cutting is to oxidize fat while preserving as much muscle as possible. The larger the calorie deficit, the faster one will lose weight. However, a large calorie deficit will also create the risk of losing muscle tissue. The bulking and cutting strategy is considered effective because there is a well-established link between muscle hypertrophy and being in a state of positive energy balance. A sustained period of caloric surplus will allow the athlete to gain more fat-free mass than they could otherwise gain under eucaloric conditions. Some gain in fat mass is expected, which athletes seek to oxidize in a cutting period while maintaining as much lean mass as possible. However, it is unclear whether one can maintain enough fat-free mass during cutting for the overall process to be worth it.

In 1999 Rhino Records released the group's first box set, Long Train Runnin': 1970–2000, which featured remastered tunes from the band's entire catalog, a new studio recording of the live concert staple "Little Bitty Pretty One" and an entire disc of previously unreleased studio outtakes and live recordings. And Rhino's release the following year, Sibling Rivalry, was the band's first new studio album since 1991. The material reflected contributions from both Knudsen and McFee, ranging from rock to hip-hop, jazz, adult contemporary and country. The album sold poorly, reflecting the declining sales throughout the adult-oriented rock musical scene. On June 22, 2001, while heading to a show at Caesars Tahoe in Lake Tahoe, Hossack suffered multiple fractures in a motorcycle accident on Highway 88 and had to be airlifted to a Sacramento-area hospital, where he underwent surgery. Drummer and percussionist M. B. Gordy was recruited to fill in for Hossack. After being sidelined for months, Hossack returned to the band in mid-2002. Gordy remained with the band as an auxiliary percussionist until 2005. Saxophonist Ed Wynne filled in for Marc Russo on the Doobies' 2002 summer tour. On October 26, 2004, the Doobie Brothers released Live at Wolf Trap, a live album recorded at Wolf Trap National Park for the Performing Arts in Vienna, Virginia on July 25 of that year. The album features the final recordings of drummer and vocalist Keith Knudsen, who died in February 2005. Ed Toth, from the band Vertical Horizon, took over for Knudsen.

== Advantages == Space optimization: Vertical farming and advanced control technologies maximize the use of limited spaces. Resource management: Reduced water and fertilizer consumption through the recycling of nutrient solutions. Protection for sensitive species: Controlled conditions shield plants from climatic extremes, pests and diseases. Hydrozones lie at the intersection of urban agriculture innovations, environmental concerns, and biodiversity conservation efforts. Notable examples include specialized botanical gardens, cultivation facilities for threatened endemic species, and domestic spaces for advanced horticulture enthusiasts.

Sources: en.wikipedia.org

Frequently asked questions

What is SR9009?

It is a synthetic REV-ERB agonist used mainly in preclinical research. It is not an approved medicine for human use.

How does it work?

It binds to REV-ERBα and REV-ERBβ, nuclear receptors involved in circadian and metabolic gene regulation. This can alter transcription of genes related to lipid and glucose metabolism in experimental models.

Is it proven to increase endurance in humans?

No controlled human trials have established that effect. Endurance findings come primarily from rodent studies, and human responses remain unknown.

What is SR9009?

SR9009 is a synthetic REV-ERB agonist used in laboratory research. It is not an approved drug, and its effects in humans are not well characterized. It is often sold as a research chemical under the name Stenabolic.

Network